Proteasome Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2028

  • Single User License $3500

Proteasome Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2028

Status : September, 2022 | Medical Devices

Report Digest


Global Proteasome Inhibitors Market - Snapshot

Rise in the prevalence of incidences of cancer to bolster growth of the global proteasome inhibitors market in the years to come. The proteasome refers to a cell-based protein degradation system that can break down a wide range of proteins into short polypeptides and amino acids. Proteasomes are made up of protein and need ATP (Adenosine Triphosphate) to function. Proteasomes feature openings on both sides of their ends that allow proteins to attach and disintegrate. In a human cell, there are approximately 30,000 proteasomes.

Excess enzymes are removed during protein digestion, and amino acids are provided for fresh protein synthesis. Proteasome inhibitors stop the proteasome and the cellular complex that breaks down proteins from moving around. Protein inhibitors prevent pro-apoptotic factors like the p53 protein from degrading. Proteasome inhibitors are being researched as well as utilized to treat cancer.

The global proteasome inhibitors market are predicted to be driven by a rise in the prevalence as well as occurrence of cancer across the globe. As cancer cells have a larger number of proteasome activity, the business for myeloma medications is the target segment.

Furthermore, research on proteasome inhibitors by research organizations and industry is likely to propel the market in the forthcoming years. The role of research methods in the global proteasome inhibitors market is to investigate different health-related concerns such as multiple myeloma.

Multiple myeloma and solid tumors have a limited number of authorized medicines. As a result, the indications have a large unmet therapeutic demand. Since this complicated pathophysiology of myeloma makes it difficult for pharmaceutical companies to produce therapies, there are only three branded and one-proteasome inhibitors in the market.

These considerations have created enormous financial prospects for companies developing medications to treat myeloma. Despite the fact that multiple myeloma is a rare disease, it has a overall high frequency. Pancreatic cancer therapy options are similarly restricted on the market.

Companies have been developing them in the late phases of clinical trials for multiple myeloma and medications for pancreatic cancer to get a presence on the market. These factors are likely to lead to the growth of the global proteasome inhibitors market.

Global Proteasome Inhibitors Market: Overview

Proteasome refers to a process of degradation of protein degradation within the cell that can assimilate various protein into short polypeptides and amino acids. Proteasome are comprised of protein and they need Adenosine Triphosphate (ATP) to function. Proteasome come with the opening at both sides of the ends so that the protein is attached for the purpose of degradation. Nearly 30,000 proteasomes exist in a human cell.

The absorption of proteins eliminates extra enzymes and provides amino acids for synthesis of new protein. Proteasome inhibitors obstruct the movement of cellular complex and proteasome, which break down the proteins. Protein inhibitors influence the breaking down of pro-apoptotic factors like p53 protein. Proteasome inhibitors finds its application in the development of research tools and treatment of cancers.

The global proteasome inhibitors market has been segmented on the basis of the following parameters: drugs, medical condition, end user, and region.

Global Proteasome Inhibitors Market: Notable Developments

Some of the leading developments pertaining to the global proteasome Inhibitors market are mentioned below:

  • In 2018, Tokyo-based Takeda Pharmaceutical Co. completed the acquisition of Ireland-based drugmaker Shire PLC. Following the acquisition, Shire PLC became a wholly owned subsidiary. Takeda Pharmaceutical Co. is famed for its expertise in neuroscience, oncology, and gastroenterology, and its objective is to increase sales of medicines for rare illness such as hemophilia. Shire PLC is an expert in the treatment for such rare diseases. Takeda Pharmaceutical Co also aims to expand its business in the U.S. market through the deal.
  • In 2019, Johnson & Johnson acquired U.S.-based Auris Health, Inc. Johnson and Johnson will take advantage of the latter’s technology of robotic platform, which is presently utilized in therapeutic and diagnostic procedures of the lung. Johnson & Johnson will, hence, further its commitment of battling lung cancer and improve its portfolio of digital surgery across multiple surgical specialties.

Some of the most prominent competitors operating in the competitive landscape of global proteasome inhibitors market include –

  • Takeda Pharmaceutical Company Limited
  • TG Therapeutics Inc.
  • Millennium Pharmaceuticals Inc
  • Johnson & Johnson’s
  • MimiVAx LLC

The proteasome inhibitors market is concentrated to some extent with handful of players dominating the shares of global proteasome inhibitors market. The market is experiencing a growing collaboration between market vendors, which will substantially diminish the market competition amongst vendors.

Global Proteasome Inhibitors Market: Growth Drivers

Prevalence of Various Types of Cancer Triggers Market Growth

The global proteasome inhibitors market is likely to be driven by the rise in prevalence of various types of cancers across the globe. The market for myeloma drugs is the target of global proteasome inhibitors market as the cancer cells have higher number of proteasome activity.

Furthermore, industry and research institutes driving the growth of the market carry out the research on proteasome inhibitors. Research tools explore various segments of health issues such as multiple myeloma and hence triggers growth of the global proteasome inhibitors market. A case in point is launch of Ninlaro to the market by Takeda Pharmaceutical Company Limited in 2015.

Proteasome inhibitors are often regarded as safe. However, the treatment utilizing these drugs could result in severe side-effects in a few patients. For example, treatment with Carfilzomib might cause harmful effects such as liver failure, lung damage, blood clots, pulmonary hypertension, and tumor lysis syndrome. Such side-effects can restrain the growth of global proteasome inhibitors market during forecast timeframe.

Global Proteasome Inhibitors Market: Regional Outlook

The North America proteasome inhibitors market held around 47% of the total market revenue in 2018 due to the rising incidences of various types of cancer indications such as non-Hodgkin’s lymphoma and multiple myeloma.

The global proteasome inhibitors market is segmented based on:

Drug

  • Bortezomib
  • Carfilzomib
  • Ixazomib

Medical Condition

  • Lymphoma
  • Mantle Cell Lymphoma
  • Multiple Myeloma

End User

  • Hospital
  • Clinics
  • Oncology Centers

The reports at TMR Research provide qualitative solutions that break the barriers of doubt or uncertainties when the stakeholders plan to expand their growth reach. The researchers compile the necessary information that enlightens the CXOs about the current growth opportunities in a specific market and enables them to make the most of the opportunities.

TMR Research is a leader in developing well-researched reports. The expertise of the researchers at TMR Research makes the report stand out from others. TMR Research reports help the stakeholders and CXOs make impactful decisions through a unique blend of innovation and analytical thinking. The use of innovation and analytical thinking while structuring a report assures complete and ideal information of the current status of the market to the stakeholders.

TMR Research has rich experience in developing state-of-the-art reports for a wide array of markets and sectors. The brilliance of the experts at TMR Research and their alacrity to conduct thorough research and create phenomenal reports makes TMR Research better than others.

5-Point Growth Formula

The 5-point growth formula developed by TMR Research provides an insight to the stakeholders and CXOs about the current situation in the market. The growth formula makes the report a perfect companion for the stakeholders and CXOs.

The 5-point growth formula includes the following points:

  • Current and Future Threats
  • Accurate Trend Analysis
  • Regional Assessment
  • Industrial Analogy
  • COVID-19 Impact

Current and Future Threats

Along with studying the opportunities necessary for growth, threats are also an important aspect to look upon for the companies and stakeholders in a specific sector. TMR Research studies every negative aspect that will hinder the growth of a specific area of business and includes it in the report. The stakeholders and CXOs will have the benefit of assessing the threat and take the necessary steps to prevent the hindrance caused due to the threats.

Accurate Trend Analysis

Keeping up with the latest trends is crucial in any business or sector. While stakeholders are aware of the trends that are on the surface, TMR Researchers find trends that are deeply entrenched in the particular market or sector. The reports are constantly updated with the latest trends so that the stakeholders and CXOs can derive benefits from the trends and generate good revenues.

Regional Assessment

Demography forms an important part of the growth pattern of all the markets. Diving deep into the demographics enables maximum output from specific areas. The TMR Research team assesses every region and picks out the vital points that have a large impact on the growth of a market.

Industrial Analogy

The analysts at TMR Research conduct an all-round analysis on the competitive landscape of the market. The observations recorded by the analysts are added to the reports so that every stakeholder gets a glimpse of the competitive scenario and frame their business plans according to the situation.

COVID-19 Impact

The COVID-19 outbreak has changed the growth projections of numerous sectors and businesses. The analysts at TMR Research have conducted a conscientious survey on the markets after the pandemic struck. The analysts have put forth their brilliant and well-researched opinions in the report. The opinions will help the stakeholders to plan their strategy accordingly.

The reports offer answers to the top 7 questions that revolve around the growth of the market

  • What are the diverse growth parameters influencing the market?
  • Which regions will contribute largely to the growth of the market
  • What are the recent innovations and technological advancements in the market?
  • What are the emerging trends across the market?
  • How has COVID-19 affected the market?
  • What will be the post-pandemic scenario of the market?
  • What are the major threats that will dent the growth prospects of the market?